Yahoo Finance

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of ...
Yahoo Finance

Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer

CAMBRIDGE, Mass., March 18, 2026--(BUSINESS WIRE)--Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of ...
C&EN

Crossbow draws $80 million in series A

Crossbow Therapeutics has landed $80 million in series A funding led by Pfizer Ventures and MPM BioImpact for the development of cancer immunotherapies. The company’s pipeline consists of antibodies ...
markets.financialcontent

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer

Biotechnology investors MPM BioImpact and Pfizer Ventures led the financing round CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company developing a ...
Morningstar%2c Inc.

Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer

Investment enables continued clinical development of T-Bolt™ therapies, including completion of CBX-250 Phase 1 trial and initiation of CBX-663 clinical trial Preclinical and translational updates on ...